Boehringer Ingelheim Pharmaceuticals, Inc.
NEWS
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
The AMR Action Fund is ramping up its infrastructure – announcing yesterday that former Novartis Venture Funds Head, Henry Skinner, will take the helm as the organization’s first chief executive officer.
It was a very busy week for clinical trial updates. Here’s a look.
Boehringer Ingelheim and Eli Lilly and Company announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
The approval was based on two randomized open-label clinical trials that evaluated the combination of empagliflozin, linagliptin and metformin and their individual components in healthy adults.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
Boehringer’s global head of information technology, Michael Schmelmer, will replace Menne on Jan. 1, 2018.
JOBS
IN THE PRESS